Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics

Simply Wall St.07-03

In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648654471?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-07-03 14:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648654471","market":"sg","top_or_hot":-1,"title":"Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics","media":"Simply Wall St.","content":"<div>\n<p>In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/why-labcorp-holdings-lh-is-up-77-after-expanding-advanced-at\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-03 14:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/why-labcorp-holdings-lh-is-up-77-after-expanding-advanced-at><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/why-labcorp-holdings-lh-is-up-77-after-expanding-advanced-at\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4195","symbol_name":"互助储蓄与抵押信贷金融服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/why-labcorp-holdings-lh-is-up-77-after-expanding-advanced-at","article_id":"2648654471","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/why-labcorp-holdings-lh-is-up-77-after-expanding-advanced-at","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648654471","pubTimestamp":1783060407,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered for eligible Medicare beneficiaries.\nTogether, these tools suggest Labcorp is deepening its role in simplifying early detection of liver and colorectal disease through less invasive, broadly accessible...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4195":"互助储蓄与抵押信贷金融服务","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","HBCP":"Home Bancorp Inc","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0251142724.SGD":"Fidelity America A-SGD","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4585":"ETF&股票定投概念","BK4157":"电子设备和仪器","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AEIS":"先进能源工业公司","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LH":"徕博科","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4211":"区域性银行","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4196":"保健护理服务"},"translate_title":"为什么Labcorp Holdings(LH)在扩展先进的家庭和血液诊断后上涨7.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBCP":1.5,"AEIS":1.5,"LH":1.5},"content_text":"In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered for eligible Medicare beneficiaries. Together, these tools suggest Labcorp is deepening its role in simplifying early detection of liver and colorectal disease through less invasive, broadly accessible diagnostics. We’ll now examine how the expansion of Labcorp’s advanced blood and RNA-based tests may influence its longer-term investment narrative. AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementLabcorp Holdings Investment Narrative RecapTo own Labcorp, you need to believe in its role as a scaled, innovation-focused diagnostics provider that can keep adding clinically relevant tests while managing cost and reimbursement pressures. The latest launches in liver and colorectal screening support that story, but do not materially change the near term focus on execution against 2026 revenue guidance and on managing pricing and reimbursement risks, including potential pressures from PAMA and competitive bidding. Among the recent announcements, the nationwide rollout and Medicare coverage of ColoSense stands out as most relevant here, because it shows how Labcorp can extend its footprint in cancer screening using newer modalities like RNA-based stool tests. That kind of expansion in oncology and preventive testing sits directly alongside MASLD and MASH blood tools as part of the same catalyst: growing test breadth to capture more volume while trying to offset reimbursement headwinds. Yet while this growth in advanced testing is encouraging, investors should also be aware of how potential reimbursement changes could... Read the full narrative on Labcorp Holdings (it's free!)Labcorp Holdings’ narrative projects $16.3 billion revenue and $1.3 billion earnings by 2029.Uncover how Labcorp Holdings' forecasts yield a $310.12 fair value, a 8% upside to its current price.Exploring Other PerspectivesLH 1-Year Stock Price Chart Three Simply Wall St Community fair value estimates for Labcorp span about US$260 to US$518 per share, showing very different expectations for upside. Against that backdrop, ongoing concerns about PAMA and broader pricing pressure could shape how those varied views translate into future revenue and earnings resilience.Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth as much as 81% more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Labcorp Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.Ready For A Different Approach?Opportunities like this don't last. These are today's most promising picks. Check them out now:We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648654471","isCrawlerRequest":true}